Sanofi Pharmaceuticals Phase I and Phase II
Sanofi is the 9th largest pharmaceutical manufacturer in the world. Headquartered in France, Sanofi has committed to meeting the carbon emission targets set in the Paris Climate Accord, even at its facilities located in the US.
In 2022, Sanofi partnered with Millig Design Build to identify energy conservation opportunities at its Framingham, Massachusetts campus.
Through an IGA, Millig worked closely with Sanofi’s facilities team to evaluate multiple upgrade options, which included the site’s central boiler and chilled water plants. The existing Building 55 Chilled Water Plant was built in 2006 and included four 750 ton chillers supported by constant-speed primary pumps. This resulted in excessive wasted energy during periods of low demand. The existing Building 68 Chilled Water Plant did not have optimized Sequences of Operations or proper chiller staging, in addition to constant speed pumping.
Solutions:
Millig’s engineers performed rigorous modeling and analysis to determine the expected post-installation performance of optimized chiller plants with variable speed pumping. A detailed design package was developed, vetted with multiple vendors, and competitively bid to secure the best value. All of this implementation happened with minimum disruption to Sanofi’s day-to-day operations thanks to proactive schedule coordination.
